Behandlung von Vorhofflimmern in der Hausarztpraxis

Vorhofflimmern ist eine häufige Herzrhythmusstörung, die in den meisten Fällen ambulant durch den Hausarzt behandelt werden kann. Dabei sind drei wesentliche Themen mit dem Patienten zu besprechen: Antikoagulation, Frequenzkontrolle und Rhythmus-Erhaltung. Den Empfehlungen zur Diagnostik und Therapie des VHF liegt in diesem Beitrag eine Leitlinie der European Society of Cardiology (ESC) zugrunde [1].

Schlüsselwörter

Vorhofflimmern - Antikoagulation - Schlaganfall - Kardioversion

• Literaturverzeichnis

• 1 Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373-498
• 2 Schnabel RB, Wilde S, Wild PS. et al. Atrial fibrillation: its prevalence and risk factor profile in the German general population. Dtsch Arztebl Int 2012; 109: 293-239
• 3 Benjamin EJ, Wolf PA, D'Agostino RB. et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-952
• 4 Perez MV, Mahaffey KW, Hedlin H. et al. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med 2019; 381: 1909-1917
• 5 William AD, Kanbour M, Callahan T. et al. Assessing the accuracy of an automated atrial fibrillation detection algorithm using smartphone technology: The iREAD Study. Heart Rhythm 2018; 15: 1561-1565
• 6 Gleason KT, Nazarian S, Dennison Himmelfarb CR. Atrial Fibrillation Symptoms and Sex, Race, and Psychological Distress: A Literature Review. J Cardiovasc Nurs 2018; 33: 137-143
• 7 Li W, Seo J, Kokkinidis DG. et al. Efficacy and safety of vitamin-K antagonists and direct oral anticoagulants for stroke prevention in patients with heart failure and sinus rhythm: An updated systematic review and meta-analysis of randomized clinical trials. Int J Stroke 2023; 18: 392-399
• 8 Berg DD, Ruff CT, Jarolim P. et al. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation 2019; 139: 760-771
• 9 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100
• 10 Ouellet GM, O'Leary JR, Leggett CG. et al. Benefits and harms of oral anticoagulants for atrial fibrillation in nursing home residents with advanced dementia. J Am Geriatr Soc 2023; 71: 561-568
• 11 Lip GY, Frison L, Halperin JL. et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41: 2731-2738
• 12 Arzneimittelkommission der deutschen Ärzteschaft. Orale Antikoagulation bei nicht valvulärem Vorhofflimmern – Empfehlungen zum Einsatz der direkten oralen Antikoagulanzien Dabigatran (Pradaxa), Apixaban (Eliquis), Edoxaban (Lixiana) und Rivaroxaban (Xarelto). 3. Aufl. 2019 Accessed November 22, 2023 at: https://www.akdae.de/arzneimitteltherapie/lf/oakvhf
• 13 Eikelboom JW, Connolly SJ, Brueckmann M. et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369: 1206-1214
• 14 Kim JY, Kim SH, Myong JP. et al. Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis. J Am Coll Cardiol 2019; 73: 1123-1131
• 15 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962
• 16 Heidbuchel H, Verhamme P, Alings M. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507
• 17 Mainz A. Medikamentenmonitoring – vom Kopf auf die Füße!. Z Allg Med 2014; 90: 54-55
• 18 Reddy VY, Doshi SK, Kar S. et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol 2017; 70: 2964-2975
• 19 Chang SH, Chou IJ, Yeh YH. et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA 2017; 318: 1250-1259